

National Comprehensive
Cancer Network®

NCCN

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Hematopoietic Cell Transplantation (HCT): Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease

Version 1.2020 — October 30, 2019

NCCN.org

Continue



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2020 Hematopoietic Cell Transplantation

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

***Ayman Saad, MD/Chair † §**
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

***Marcos de Lima, MD/Vice Chair †**
Case Comprehensive Cancer Center/University
Hospitals Seidman Cancer
Center and Cleveland Clinic Taussig
Cancer Institute

Sarah Anand, MD † †
University of Michigan
Rogel Cancer Center

Vijaya Raj Bhatt, MBBS † §
Fred & Pamela Buffett Cancer Center

Ryan Bookout, PharmD † Σ
Moffitt Cancer Center

George Chen, MD † §
Roswell Park Comprehensive Cancer Center

Daniel Couriel MD, MS † † § P
Huntsman Cancer Institute
at the University of Utah

Antonio Di Stasi, MD † †
O'Neal Comprehensive
Cancer Center at UAB

Areej El-Jawahri, MD † † §
Massachusetts General Hospital
Cancer Center

Sergio Giralt, MD †
Memorial Sloan Kettering Cancer Center

Jonathan Gutman, MD †
University of Colorado Cancer Center

Vincent Ho, MD † †
Dana-Farber/Brigham and Women's
Cancer Center

Mitchell Horwitz, MD † †
Duke Cancer Institute

Joe Hsu, MD Φ
Stanford Cancer Institute

Mark Juckett, MD †
University of Wisconsin
Carbone Cancer Center

Mohamed Kharfan Dabaja, MD †
Mayo Clinic Cancer Center

Alison W. Loren, MD, MSCE † §
Abramson Cancer Center
at the University of Pennsylvania

Javier Meade, MD †
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Marco Mielcarek, MD, PhD † §
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Jonathan Moreira, MD † †
Robert H. Lurie Comprehensive Cancer Center
of Northwestern University

Ryotaro Nakamura, MD †
City of Hope National Medical Center

Yago Nieto, MD, PhD †
The University of Texas
MD Anderson Cancer Center

Juliana Roddy, PharmD, BCOP † § Σ
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Gowri Satyanarayana, MD Φ
Vanderbilt-Ingram Cancer Center

Mark Schroeder, MD †
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

Carlyn Rose Tan, MD † †
Fox Chase Cancer Center

Dimitrios Tzachanis MD, PhD † †
UC San Diego Moores Cancer Center

NCCN
Jennifer Burns
Lenora A. Pluchino, PhD

§ Hematopoietic cell transplantation
‡ Hematology/Hematology oncology
Φ Infectious diseases
P Internal medicine
† Medical oncology
Σ Pharmacology
* Discussion Section Writing Committee

Continue

[NCCN Guidelines Panel Disclosures](#)





National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2020 Hematopoietic Cell Transplantation

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

[NCCN Panel Members](#)

[Introduction \(INTRO\)](#)

[Indications for Transplantation \(HCT-1\)](#)

[Pre-Transplant Recipient Evaluation \(HCT-2\)](#)

[Diagnosis/Workup of Graft-Versus-Host Disease \(GVHD-1\)](#)

[Management of Acute GVHD \(GVHD-2\)](#)

[Management of Chronic GVHD \(GVHD-4\)](#)

[Acute GVHD: Staging and Grading \(GVHD-A\)](#)

[Chronic GVHD: Diagnosis \(GVHD-B\)](#)

[Chronic GVHD: Grading \(GVHD-C\)](#)

[GVHD Steroid Response Definitions/Criteria \(GVHD-D\)](#)

[Suggested Systemic Agents for Steroid-Refractory GVHD \(GVHD-E\)](#)

[Discussion \(MS-1\)](#)

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical_trials/member_institutions.aspx](#).

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2019.



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2020 Hematopoietic Cell Transplantation

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

INTRODUCTION

The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) pertain to the management of adult patients undergoing HCT for malignant diseases.

The initial version of the Guidelines addresses pre-transplant recipient evaluation and management of acute/chronic graft-versus-host disease (GVHD). Additional topics will be addressed in subsequent versions.

**Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2020 Hematopoietic Cell Transplantation

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

INDICATIONS FOR TRANSPLANTATION

Indications for hematopoietic cell transplantation (HCT) vary by disease.

Indications for HCT can be found in the following NCCN Guidelines:

- [NCCN Guidelines for Acute Lymphoblastic Leukemia](#)
- [NCCN Guidelines for Acute Myeloid Leukemia](#)
- [NCCN Guidelines for B-Cell Lymphomas](#)
- [NCCN Guidelines for Central Nervous System Cancers](#)
- [NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](#)
- [NCCN Guidelines for Chronic Myeloid Leukemia](#)
- [NCCN Guidelines for Gestational Trophoblastic Neoplasia](#)
- [NCCN Guidelines for Hodgkin Lymphoma](#)
- [NCCN Guidelines for Multiple Myeloma](#)
- [NCCN Guidelines for Myelodysplastic Syndromes](#)
- [NCCN Guidelines for Myeloproliferative Neoplasms \(MPN\)](#)
- [NCCN Guidelines for Primary Cutaneous Lymphoma](#)
- [NCCN Guidelines for Systemic Light Chain Amyloidosis](#)
- [NCCN Guidelines for Systemic Mastocytosis \(SM\)](#)
- [NCCN Guidelines for T-Cell Lymphomas](#)
- [NCCN Guidelines for Testicular Cancer](#)
- [NCCN Guidelines for Waldenström Macroglobulinemia](#)

[Pre-Transplant Recipient Evaluation](#)
(see HCT-2)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.